AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients
30 janv. 2018 16h01 HE
|
AveXis, Inc.
CHICAGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
22 janv. 2018 16h05 HE
|
AveXis, Inc.
CHICAGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,509,840 shares of its common stock at...
AveXis Announces Pricing of Public Offering of Common Stock
16 janv. 2018 20h18 HE
|
AveXis, Inc.
CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,921,600 shares of its common stock at a public offering...
AveXis Announces Proposed Public Offering of Common Stock
16 janv. 2018 07h25 HE
|
AveXis, Inc.
CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its common...
AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy
16 janv. 2018 07h20 HE
|
AveXis, Inc.
– Company to expand study of AVXS-101 into additional SMA populations including pre-symptomatic, older pediatric Type 2 and Type 3 SMA patients – – First patient dosed in Phase 1 trial of AVXS-101 in...
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
08 janv. 2018 08h00 HE
|
AveXis, Inc.
AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMAAmended agreement permits assignment by AveXis upon a change of control without REGENXBIO’s...
AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1
04 janv. 2018 16h00 HE
|
AveXis, Inc.
– Company to submit information requested by FDA to the IND on an on-going basis – – AveXis plans to request a pre-BLA meeting in Q2 2018 – – Conference call and webcast today at 4:30 pm EST – ...
AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101
13 déc. 2017 16h00 HE
|
AveXis, Inc.
– The FDA notified AveXis it may initiate the Phase 1 trial in SMA Type 2 based on a review of data provided by the company; trial to commence immediately – – The trial will evaluate...
AveXis Reports Third Quarter 2017 Financial and Operating Results
09 nov. 2017 16h00 HE
|
AveXis, Inc.
– First patient has been dosed in pivotal trial of AVXS-101 for SMA Type 1 – – Conference call and webcast November 9 at 4:30 p.m. EST – CHICAGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc....
AveXis to Report Third Quarter 2017 Financial and Operating Results
02 nov. 2017 08h00 HE
|
AveXis, Inc.
CHICAGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...